Vanguard Personalized Indexing Management LLC Buys New Shares in Novavax, Inc. $NVAX

Vanguard Personalized Indexing Management LLC purchased a new stake in Novavax, Inc. (NASDAQ:NVAX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,487 shares of the biopharmaceutical company’s stock, valued at approximately $72,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Signaturefd LLC raised its position in shares of Novavax by 47.2% during the second quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 3,122 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in Novavax during the first quarter valued at about $71,000. Wealth Enhancement Advisory Services LLC acquired a new position in Novavax in the 2nd quarter valued at approximately $73,000. Kapitalo Investimentos Ltda acquired a new position in Novavax in the 2nd quarter valued at approximately $79,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Novavax in the 1st quarter worth approximately $99,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Stock Up 1.9%

Shares of NASDAQ NVAX opened at $8.52 on Monday. Novavax, Inc. has a 52-week low of $5.01 and a 52-week high of $11.55. The company has a debt-to-equity ratio of 5.93, a quick ratio of 2.34 and a current ratio of 2.36. The business has a fifty day moving average of $8.40 and a two-hundred day moving average of $7.44. The stock has a market cap of $1.38 billion, a PE ratio of 3.74, a PEG ratio of 0.13 and a beta of 2.74.

Novavax (NASDAQ:NVAX) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.69. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The business had revenue of $239.24 million during the quarter, compared to analysts’ expectations of $149.19 million. During the same quarter last year, the company posted $0.99 EPS. The firm’s revenue for the quarter was down 42.4% on a year-over-year basis. As a group, equities research analysts expect that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on NVAX shares. Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a research note on Saturday. Cantor Fitzgerald began coverage on shares of Novavax in a report on Friday. They issued an “overweight” rating and a $18.00 price target on the stock. HC Wainwright raised their price objective on shares of Novavax from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Bank of America reissued an “underperform” rating and issued a $7.00 target price (down previously from $9.00) on shares of Novavax in a research note on Wednesday, August 20th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $11.33.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.